Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

56.77 +0.37 (+0.65%)
Streaming Delayed Price Updated: 9:34 AM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2
...
28 29 30 31 32 33 34 35 Next >
News headline image
Week In Review: Xbiome Acquires Diabetic Foot Ulcer Therapy In $139 Million Deal ↗
Xbiome, a Shenzhen AI-based microbiome drug development company, in-licensed China rights to an inflammatory disease therapy developed by Aurealis, a Swiss synthetic biology company, in a deal worth up... 
Via Talk Markets
News headline image
Here's How Much You Would Have Made Owning CRISPR Therapeutics Stock In The Last 5 Years ↗
CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 14.31% on an annualized basis. Buying $1,000 In CRSP: 5 years ago, an investor could have... 
Via Benzinga
News headline image
Stock Market Rebound Fizzles Amid Hawkish Fed; Taiwan Semiconductor Breaks Out, JPMorgan Tumbles: Weekly Review ↗
A rebound from Monday's lows faded, with the key indexes all down for the week. 
Via Investor's Business Daily
News headline image
The Journey To Rewrite Human DNA Is About To Get Wild, Thanks To Pfizer, Bayer, Intellia And Other CRISPR stocks ↗
Big Pharma is paying attention to CRISPR stocks. Could that alight shares this year? 
Via Investor's Business Daily
News headline image
3 Deep Value Moonshots to Ride Out Powell’s Taper Tantrum ↗
These three companies might seem like zombies compared to other investing opportunities, but they'll be robust during the Fed taper. 
Via InvestorPlace
News headline image
Pfizer Makes Foray Into CRISPR, Inking $1.35 Billion Deal With Beam Therapeutics ↗
The companies hope to cure diseases of the liver, muscle and central nervous system. 
Via Investor's Business Daily
News headline image
7 Stock Bargains Worth a Look After the Most Recent Pullback ↗
Value investors may choose to buy stocks that are out of favor and from among beaten up stock bargains in a variety of sectors. 
Via InvestorPlace
News headline image
Top 5 Moonshots for 2022 Countdown: My No. 5 Pick ↗
2021 wasn't the best year for gene-editing stocks, but expect a comeback in 2022. Here's the top gene-editing choice for next year. 
Via InvestorPlace
News headline image
Biotech Playbook 2021 Part 2: Rotation Rally Brings Relief after FED Pivot ↗
The new aggressive Fed taper combined with a rise in interest rates for 2022 adds a new element of risk to portfolio management. Monetary policy is a headwind for 2022. 
Via Talk Markets
News headline image
10 Bargain Stocks to Buy After Falling 30% in 2021 ↗
If you’re looking for bargain stocks to buy that are down 30% or more in 2021, that’s not an easy task. Here are 10 that fit the bill. 
Via InvestorPlace
News headline image
Biotech Playbook 2021: No Help From Small Caps In Q4 ↗
Mid-cap stock picks have done better today but are way off their 2021 highs. Cryoport and Veracyte are still up and look better technically. Quidel was up 5.48% today on Omicron concerns globally but... 
Via Talk Markets
News headline image
Adobe Earnings Strangle Trade ↗
Adobe announces earnings this week, and we plan on using an options strategy called a 
Via Talk Markets
News headline image
CRISPR Therapeutics Is One of Today’s Best Biotech Value Investments ↗
Don't let the downtrend in CRSP stock fool you; the company is still making headway in advancing potentially life-changing therapeutics. 
Via InvestorPlace
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For December 7, 2021 ↗
Upgrades For CarMax Inc (NYSE: 
Via Benzinga
News headline image
Why CRISPR Therapeutics Stock Sank 12.5% in November ↗
The gene-editing specialist's share price is now down roughly 54% in 2021. 
Via The Motley Fool
News headline image
Jim Cramer Shares His Thoughts On Chegg, Bristol-Myers Squibb And More ↗
On CNBC’s "Mad Money Lightning Round," Jim Cramer said with Matterport, Inc. (NASDAQ: 
Via Benzinga
News headline image
Biotech Stocks are Due for a Rally ↗
There are many rebalancing trades left in your stock portfolio but biotech is in the doldrums. 
Via Talk Markets
News headline image
Do CRISPR Therapeutics and Intellia Face a Big Safety Risk? ↗
CRISPR gene editing is promising, but there's a risk that it can cause unwanted mutations. 
Via The Motley Fool
News headline image
Better Buy: Vertex Pharmaceuticals vs. CRISPR ↗
The companies are collaborating on a potential blockbuster. 
Via The Motley Fool
News headline image
Looking for Growth in Small and Mid Cap Life Science Stocks ↗
2021 is an unusual year for biotech with a “blow-off” February high in speculative small caps. 
Via Talk Markets
News headline image
Being First Is Not Enough For Crispr Therapeutics ↗
CRSP stock is facing competition and meeting skepticism as the company tries to turn CRISPR-CAS9 into profitable drug therapies. 
Via InvestorPlace
News headline image
Why CRISPR Therapeutics Stock Fell 18.4% in October ↗
The gene-editing specialist's stock is now down roughly 37% year to date. 
Via The Motley Fool
News headline image
Why Vertex Is Striking Another Gene-Editing Deal With a Company Not Named CRISPR Therapeutics ↗
Vertex plans to develop gene-editing therapies with Mammoth Biosciences. 
Via The Motley Fool
News headline image
3 Things About CRISPR Therapeutics That Smart Investors Know ↗
The company's value isn't reflected in typical performance metrics. 
Via The Motley Fool
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2021 ↗
Upgrades Maxim Group upgraded the previous rating for Indaptus Therapeutics Inc (NASDAQ: 
Via Benzinga
News headline image
2 Gene-Editing Stocks to Have on Your Radar Right Now ↗
They only have preclinical candidates for now. But these biotechs could have game-changing gene-editing therapies. 
Via The Motley Fool
News headline image
2 Top Healthcare Stocks That Could Be Bought Out in 2022 ↗
These two novel-drug makers could be top takeover targets next year. 
Via The Motley Fool
News headline image
If You Invested $3,000 in CRISPR Therapeutics in 2018, This Is How Much You Would Have Today ↗
The returns haven't been half bad, to say the least. 
Via The Motley Fool
News headline image
Crispr: A Fallen Angel In Gene Editing ↗
As with most promising biotech companies, investors bid their prices up for CRSP based on its potential for early profits. When the payoff didn't occur on schedule, investors bailed out. Once it... 
Via Talk Markets
News headline image
Market Rally Takes Hold As Leading Stocks Shine; Tesla, Taiwan Semi, Delta In Focus: Weekly Review ↗
It's a confirmed rally again, with the major indexes rebounding on strong earnings and falling yields. 
Via Investor's Business Daily
< Previous 1 2
...
28 29 30 31 32 33 34 35 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.